RLAY
Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.01
+3.27%Nov 4, 2026, 21:05 UTC
Relay Therapeutics, Inc. said enrollment in its Phase 3 ReDiscover-2 trial in second-line breast cancer is expected to be completed in mid-2027.
Source:Nov 4, 2026, 21:05 UTC
Relay Therapeutics, Inc. announced a second vascular-anomalies program involving a mutant-selective TIE2 inhibitor.
Source:Nov 4, 2026, 21:05 UTC
Relay Therapeutics, Inc. appointed Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies.
Source:Nov 4, 2026, 21:05 UTC
Relay Therapeutics, Inc. reported third-quarter 2026 financial results, including approximately $849 million in cash, cash equivalents and investments at quarter-end.
Source:Nov 4, 2026, 21:05 UTC
Relay Therapeutics, Inc. announced plans to present updated data from its ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies at the 68th American Society of Hematology Annual Meeting and Exposition.
Source:Oct 28, 2026, 20:12 UTC
Relay Therapeutics, Inc. said it will report its third-quarter 2026 financial results and corporate highlights after U.S. markets close on November 4, 2026.
Source:Aug 7, 2026, 00:12 UTC
Relay Therapeutics, Inc. reported a second-quarter loss of $0.41 per share, in line with the Zacks Consensus Estimate and unchanged from the year-ago quarter.
Source: